The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations – the Lung Cancer Mutation Consortium (LCMC2)

PURPOSE: Multiplex genomic profiling is standard of care for patients with advanced lung adenocarcinomas. The Lung Cancer Mutation Consortium (LCMC) is a multi-institutional effort to identify and treat oncogenic driver events in patients with lung adenocarcinomas. PATIENTS AND METHODS: Sixteen U.S....

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cancer Res
Päätekijät: Aisner, Dara L., Sholl, Lynette M., Berry, Lynne D., Rossi, Michael R., Chen, Heidi, Fujimoto, Junya, Moreira, Andre L., Ramalingam, Suresh S., Villaruz, Liza C., Otterson, Gregory A., Haura, Eric, Politi, Katerina, Glisson, Bonnie, Cetnar, Jeremy, Garon, Edward B., Schiller, Joan, Waqar, Saiama N., Sequist, Lecia V., Brahmer, Julie, Shyr, Yu, Kugler, Kelly, Wistuba, Ignacio I., Johnson, Bruce E., Minna, John D., Kris, Mark G., Bunn, Paul A., Kwiatkowski, David J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7008001/
https://ncbi.nlm.nih.gov/pubmed/29217530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2289
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia